- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04553393
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden
Treatment of Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Plus Epigenetic Agents in Aggressive Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients With Huge Tumor Burden
Study Overview
Status
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Weidong Han, M.D.
- Phone Number: +861055499341
- Email: hanwdrsw@sina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Recruiting
- Biotherapeutic Department of Chinese PLA General Hospital
-
Principal Investigator:
- Yajing Zhang, M.D
-
Principal Investigator:
- Zhiqiang Wu, M.D
-
Principal Investigator:
- Yao Wang, M.D.
-
Principal Investigator:
- Yang Liu, M.D.
-
Principal Investigator:
- Qingming Yang, M.D.
-
Sub-Investigator:
- Chuan Tong, M.S.
-
Sub-Investigator:
- Chunmeng Wang, M.S.
-
Sub-Investigator:
- Dongdong Ti, M.S.
-
Sub-Investigator:
- Jianshu Wei, M.D.
-
Sub-Investigator:
- Deyun Chen, M.S.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥16 and ≤ 65 years.
- Sum of the Product of the perpendicular Diameters for multiple lesions, SPD ≥ 100cm^2 or the largest-diameter of tumor ≥ 10cm.
Histologically confirmed CD20+ and/or CD19+ aggressive B-cell non-Hodgkin lymphoma (NHL), including the following types defined by the World Health Organization (WHO) 2016:
- Diffuse large B-cell lymphoma (DLBCL).
- High grade B-cell lymphoma(HGBL).
- Other aggressive B-cell lymphoma.
Refractory disease or relapse after treatment with ≥2 lines of chemotherapy, including rituximab and anthracycline and either having failed autologous hematopoietic stem cell transplantation (HSCT), being ineligible for autologous HSCT or not consenting to autologous HSCT.
We defined chemotherapy-refractory disease as meeting one or more of the following criteria:
- No response to first-line therapy (primary refractory disease).
- No response to second-line or later therapy.
- Progressive disease (PD) as the best response to the most recent therapy regimen.
- Stable disease (SD) as the best response after at least 2 cycles of the most recent line of therapy with an SD duration of no longer than 6 months from the last dose of therapy.
Failure following autologous HSCT was defined as follows:
- PD or relapsed disease ≤12 months after autologous stem cell transplantation (ASCT) (requires biopsy-proven recurrence in relapsed subjects).
- No response or relapse after salvage therapy is given post-ASCT.
- PD or relapse ≥3 months after treatment with targeted CD19 therapy, including CD19 CAR T cells or anti-CD19/anti-CD3.
- Successful leukapheresis assessment and preculture of T cells.
- Life expectancy > 3 months.
Adequate organ function:
- Creatinine < 1.6 mg/dL (140 µmol/L) or creatinine clearance ≥60 mL/min.
- Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3× upper limit of the normal range.
- Bilirubin <2.0 mg/dL unless the subject had Gilbert's syndrome (<3.0 mg/dL).
- A minimum level of pulmonary reserve defined as ≤ grade 1 dyspnoea and pulse oxygenation > 91% with room air.
- Cardiac ejection fraction ≥50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings.
An adequate bone marrow reserve defined as:
- Absolute neutrophil count (ANC)>1,000/mm3.
- Absolute lymphocyte count (ALC)≥300/mm3.
- Platelet count ≥ 50,000/mm3.
- Haemoglobin > 7.0 mg/dL.
- Measurable or assessable disease according to the "IWG Response Criteria for Malignant Lymphoma" (Cheson 2014). Patients in complete remission (CR) with no evidence of disease were not eligible.
- Informed consent/assent requiring that all patients have the ability to understand and the willingness to provide written informed consent.
Exclusion Criteria:
- Patients with definite involvement of the gastrointestinal tract. Endoscopy should be performed to confirm gastrointestinal involvement in suspected patients. However, patients with central nervous system (CNS) involvement were cautiously enrolled in this clinical study.
- Detection of a clear HAMA effect in patients with prior CD19 CAR T cell treatment failure or recurrence, or negative tumour puncture detection of CD19 and CD20.
- Pregnant or lactating women.
- Uncontrolled active bacterial or viral infection (active hepatitis B or hepatitis C infection, HIV infection) or treponema pallidum infection.
- Class III/IV cardiovascular disability according to the New York Heart Association Classification and a cardiac ejection fraction ≥50%.
- History of allo-HSCT.
- Requirement for urgent therapy due to tumour mass effects such as respiratory obstruction or blood vessel compression.
- Current or expected need for systemic corticosteroid therapy.
- Any organ failure.
- Patients with a second tumour requiring therapy or intervention.
- Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 2.
- Subjects considered unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation according to the investigator's judgement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Decitabine-primed Tandem CAR19/20 engineered T cells
Tandem dual Specificity targeting CD19 and CD20 decitabine-primed CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 and improve the possibility of killing lymphoma tumor cells.
|
Tandem CAR19/20 engineered T cells
Other Names:
|
Experimental: Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide
Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
|
Tandem CAR19/20 engineered T cells
Other Names:
Chidamide will be added 1 month after responding to CART cells infusion
Other Names:
|
Experimental: Decitabine-primed Tandem CAR19/20 engineered T cells plus decitabine
Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
|
Tandem CAR19/20 engineered T cells
Other Names:
Decitabine will be added 1 month after responding to CART cells infusion
Other Names:
|
Experimental: Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide+decitabine
The combination of chidamide and decitabine can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function, induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance
|
Tandem CAR19/20 engineered T cells
Other Names:
Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: 2 years
|
2 years
|
|
Overall Survival
Time Frame: 2 years
|
2 years
|
|
Duration of Response
Time Frame: 2 years
|
2 years
|
|
Adverse events after intervention
Time Frame: 12 months
|
Safety Outcome
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate Outcome Measure
Time Frame: 2 years
|
ORR assess by investigators per the 2014 Lugano classification rate of subjects achieved objective response in all evaluable subjects
|
2 years
|
Intervention treatment-related adverse events (AEs)
Time Frame: 12 months
|
Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory research
Time Frame: 12 months
|
Track cart cells in PB after infusions by TCR, transcriptional, and epigenetic sequencing.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Weidong Han, M.D., Chinese PLA hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHN-PLAGH-BT-060
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
-
TakedaRecruitingRelapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)United States
-
Regeneron PharmaceuticalsAvailableDiffuse Large B-Cell Lymphoma (DLBCL) | Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | B-Cell Non-Hodgkin Lymphoma (NHL) | High-Grade B-Cell Lymphoma (HGBCL)
-
ADC Therapeutics S.A.No longer availableRelapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
-
Grupo Oncológico para el Tratamiento y el Estudio...UnknownFollicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.Spain
-
National Cancer Institute (NCI)CompletedHIV Infection | Clear Cell Renal Cell Carcinoma | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditionsUnited States
Clinical Trials on Decitabine-primed Tandem CAR19/20 engineered T cells
-
Han weidongRecruitingRelapsed and Refractory B-cell Non-Hodgkin's Lymphoma | Decitabine-primed Tandem CD19/CD20 CAR T CellsChina
-
Chinese PLA General HospitalCompletedRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditionsChina